Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2017-07-13
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents
NCT05126914
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
NCT00088452
Rolandic Epilepsy Genomewide Association International Study
NCT03547050
Clinical-genetic Investigations in Children With Early Infantile Epilepsies
NCT01357707
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study
NCT00041951
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The goal of this study is to find the genetic cause for JME. The investigators will do this by comparing the genetic code in JME patients with that in people who do not have epilepsy. This study will use clues from their electroencephalograph or brainwave test that is used to help diagnose epilepsy. Participants will provide a single blood sample, along with permission to collect clinical data about their diagnosis and a copy of their clinical EEG. There is no direct benefit or risk to the research participants but the results from this study may help other people with epilepsy or brain impairments in the future.
There is overwhelming evidence that JME is caused by changes in genetic code. These changes are likely to be found in more than just one gene and there may be more than one type of change. In order to find these changes, this study will look at a large number of people with JME and compare their genetic code with people who do not have epilepsy. Finding the causes of JME will lead to better understanding of its cause, new treatments, and tailoring of treatments according to a person's genetic make-up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients diagnosed with JME
People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
Blood draw
Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
Controls
People without a lifetime history of seizures.
Existing samples
Control DNA samples will be used that have been previously acquired in other studies.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood draw
Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
Existing samples
Control DNA samples will be used that have been previously acquired in other studies.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age of myoclonus onset 10-25 years
* Seizures comprising predominant or exclusive early morning myoclonus of upper extremities
* EEG interictal generalized spikes and/or polyspike and waves with normal background
* Current age 10-40 years
Exclusion Criteria
* EEG showing predominant focal interictal epileptiform discharges or abnormal background
* Any evidence of progressive or symptomatic myoclonus epilepsy or focal seizures
* Global learning disability
* Dysmorphic syndrome
* Unable to provide informed consent
Regrettably, we are currently unable to accept self-referrals to the BIOJUME study.
10 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King's College Hospital NHS Trust
OTHER
Charles University, Czech Republic
OTHER
Hopital Universitaire Robert-Debre
OTHER
Vestre Viken Hospital Trust
OTHER
The Hospital for Sick Children
OTHER
Cardiff University
OTHER
Odense University Hospital
OTHER
King's College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
K Pal, MD PhD
Role: PRINCIPAL_INVESTIGATOR
King's College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mount Sinai-Beth Israel Medical Center
New York, New York, United States
St Luke's Roosevelt Hospital
New York, New York, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Hospital for Sick Kids
Toronto, Ontario, Canada
Charles University
Prague, , Czechia
Danish National Epilepsy Centre
Dianalund, , Denmark
Tallinn Children's Hospital
Tallinn, , Estonia
University Robert Debré
Paris, , France
Commissione Genetica Lega Italiana contro l'Epilepssia
Roma, , Italy
Vestre Viken Health Trust, Oslo
Drammen, , Norway
Walton Centre for Neurology and Neurosurgery
Liverpool, , United Kingdom
Royal London Hospital
London, , United Kingdom
St Thomas' Hospital
London, , United Kingdom
King's College Hospital NHS Trust
London, , United Kingdom
Swansea University
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dr Lisa Strug
Role: primary
Dr Jana Zarubova
Role: primary
Dr Helle Hialgrim
Role: primary
Dr Rikke Moller
Role: backup
Dr Inga Talvik
Role: primary
Professor Stephane Auvin
Role: primary
Dr Amedeo Bianchi
Role: primary
Dr Pasquale Striano
Role: backup
Dr Jeanette Koht
Role: primary
Dr Kaja Selmer
Role: backup
Professor Anthony Marson
Role: primary
Maha Awadalla
Role: primary
Professor Michalis Koutroumanidis
Role: primary
Deb K Pal
Role: backup
Professor Mark Rees
Role: primary
Dr Rhys Thomas
Role: backup
Related Links
Access external resources that provide additional context or updates about the study.
Childhood Epilepsy website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIHR ID: MOP-142405
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
199351
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.